Author:
Suleman Sultan,Vandercruyssen Kirsten,Wynendaele Evelien,D’Hondt Matthias,Bracke Nathalie,Duchateau Luc,Burvenich Christian,Peremans Kathelijne,De Spiegeleer Bart
Abstract
Abstract
Background
Artemisinin-based fixed dose combination (FDC) products are recommended by World Health Organization (WHO) as a first-line treatment. However, the current artemisinin FDC products, such as β-artemether and lumefantrine, are inherently unstable and require controlled distribution and storage conditions, which are not always available in resource-limited settings. Moreover, quality control is hampered by lack of suitable analytical methods. Thus, there is a need for a rapid and simple, but stability-indicating method for the simultaneous assay of β-artemether and lumefantrine FDC products.
Methods
Three reversed-phase fused-core HPLC columns (Halo RP-Amide, Halo C18 and Halo Phenyl-hexyl), all thermostated at 30°C, were evaluated. β-artemether and lumefantrine (unstressed and stressed), and reference-related impurities were injected and chromatographic parameters were assessed. Optimal chromatographic parameters were obtained using Halo RP-Amide column and an isocratic mobile phase composed of acetonitrile and 1mM phosphate buffer pH 3.0 (52:48; V/V) at a flow of 1.0 ml/min and 3 μl injection volume. Quantification was performed at 210 nm and 335 nm for β-artemether and for lumefantrine, respectively. In-silico toxicological evaluation of the related impurities was made using Derek Nexus v2.0®.
Results
Both β-artemether and lumefantrine were separated from each other as well as from the specified and unspecified related impurities including degradants. A complete chromatographic run only took four minutes. Evaluation of the method, including a Plackett-Burman robustness verification within analytical QbD-principles, and real-life samples showed the method is suitable for quantitative assay purposes of both active pharmaceutical ingredients, with a mean recovery relative standard deviation (± RSD) of 99.7 % (± 0.7%) for β-artemether and 99.7 % (± 0.6%) for lumefantrine. All identified β-artemether-related impurities were predicted in Derek Nexus v2.0® to have toxicity risks similar to β-artemether active pharmaceutical ingredient (API) itself.
Conclusions
A rapid, robust, precise and accurate stability-indicating, quantitative fused-core isocratic HPLC method was developed for simultaneous assay of β-artemether and lumefantrine. This method can be applied in the routine regulatory quality control of FDC products. The in-silico toxicological investigation using Derek Nexus® indicated that the overall toxicity risk for β-artemether-related impurities is comparable to that of β-artemether API.
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Parasitology
Reference32 articles.
1. WHO: World Malaria Report, Global Malaria Programme. 2008, Geneva: World Health Organization Publication, http://whqlibdoc.who.int/publications/2008/9789241563697_eng.pdf [Accessed on June 22, 2012 at 18:50]
2. WHO: World Malaria Report, Global Malaria Programme. 2011, Geneva: World Health Organization Publication, http://www.who.int/malaria/world_malaria_report_2011/en/ [Accessed on June 22, 2012 at 19:10]
3. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD: Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet. 2012, 379: 413-10.1016/S0140-6736(12)60034-8.
4. WHO: Guidelines for the treatment of malaria. 2010, Geneva: World Health Organization
5. Ashley EA, White NJ: Artemisinin-based combinations. Cur Opin Infect Dis. 2005, 18: 531-36. 10.1097/01.qco.0000186848.46417.6c.
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献